Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Samir MacWan

Neuromuscular Medicine Rancho Mirage, CA Medical Doctor

NPI 1265558753 CMS profile 741673

72780 Country Club Dr Ste 205, Rancho Mirage, CA 92270

Open in the dashboard

General payments

$983,267

1,667 records reported · program years 2019–2025

Research payments

$11,008

Paid to them · 7 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$367,527 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Samir MacWan of Rancho Mirage, CA is reported in the CMS Open Payments database as having received $983,267 across 1,667 general payments and $11,008 in research payments paid to them. Separately, studies naming them as principal investigator received $367,527 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Neuromuscular Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $203,627 315
2025 Research $11,008 7
2024 General $255,900 415
2023 General $143,013 273
2022 General $127,887 181
2021 General $69,392 118
2020 General $55,144 115
2019 General $128,305 250

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Samir MacWan
  • Neuromuscular Medicine median
  • Middle half of Neuromuscular Medicine
  • National median

In program year 2025, general payments to Samir MacWan were reported at $203,627. Among 188 Neuromuscular Medicine profiles paid that year, the median was $530 and the middle half received between $134 and $6,440.

Show as a table
Year Samir MacWan Neuromuscular Medicine median Middle half National median
2019 $128,305 $356 $114–$4,219 $163
2020 $55,144 $287 $72–$5,632 $114
2021 $69,392 $193 $73–$1,841 $132
2022 $127,887 $362 $109–$2,461 $149
2023 $143,013 $411 $119–$3,356 $160
2024 $255,900 $394 $122–$5,116 $164
2025 $203,627 $530 $134–$6,440 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Argenx US, Inc. $218,517 265 payments
  2. Alexion Pharmaceuticals, Inc. $206,744 282 payments
  3. AbbVie, Inc. $166,518 296 payments
  4. UCB, Inc. $154,565 274 payments
  5. US WorldMeds, LLC $74,624 137 payments
  6. Allergan Inc. $64,176 120 payments
  7. Grifols USA, LLC $64,027 94 payments
  8. Catalyst Pharmaceuticals, Inc. $10,257 14 payments
  9. Biohaven Pharmaceuticals, Inc. $6,535 9 payments
  10. Amgen Inc. $3,737 9 payments
  11. Other $13,568 167 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $678,509 266 payments
  2. Consulting Fee $133,683 41 payments
  3. Travel and Lodging $124,203 375 payments
  4. Food and Beverage $41,083 970 payments
  5. Honoraria $5,700 4 payments
  6. Education $90 11 payments
Products named General payments · program years 2019–2025
  1. BOTOX $162,063 151 payments
  2. VYVGART $133,350 157 payments
  3. VYVGART Hytrulo $85,542 108 payments
  4. Soliris $79,716 146 payments
  5. ULTOMIRIS $76,417 104 payments
  6. Rystiggo $65,432 92 payments
  7. MYOBLOC $64,126 112 payments
  8. Gamunex-C $60,252 101 payments
  9. Zilbrysq $41,189 98 payments
  10. UBRELVY $28,122 64 payments
  11. Other $136,563 544 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Argenx US, Inc. $6,563 2 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $4,445 5 payments

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

2,023

Median for Neurology: 833

Drug cost

$18,570,293

Median for Neurology: $202,670

Branded share of claims

66.4%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Panzyga Immun Glob G(Igg)-Ifas/Glycine Brand 252 $4,024,237
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 325 $2,570,321
Vyvgart Hytrulo Efgartigimod-Hyaluronidas-Qvfc Brand 42 $2,062,794
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 107 $1,709,794
Soliris Eculizumab Brand 54 $1,430,639
Firdapse Amifampridine Phosphate Brand 40 $1,422,389
Gammaked Immune Globul G/Gly/Iga Avg 46 Brand 85 $1,103,542
Octagam Immun Globg(Igg)/Malt/Iga Ov50 Brand 76 $1,036,246
Gammaplex Immun Glob G(Igg)/Gly/Iga 0-50 Brand 52 $940,541
Privigen Immun Glob G(Igg)/Pro/Iga 0-50 Brand 60 $754,226

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 39 billing codes

Paid by Medicare

$217,148

Medicare's payments for the services billed

Medicare patients

850

Average age 75

Services billed

3,017

428 women, 422 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 74%
Ischemic heart disease 33%
Depression 28%
Chronic kidney disease 27%
Diabetes 23%
Osteoporosis 22%
Atrial fibrillation 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VYVGART Hytrulo
$56,015 42 —
VYVGART
$47,448 42 —
BOTOX
$43,528 — —
Rystiggo
$30,539 — —
ULTOMIRIS
$23,511 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

1,674 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neuromuscular Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record